Overview

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Immunoglobulin Fab Fragments